HOME >> MEDICINE >> NEWS
Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate

eadaches (17%) Malignancies were rare.

Physicians in Europe have become familiar with the benefits and long-term tolerability profile of ENBREL since it became commercially available over six years ago. More than 400,000 patients have been treated worldwide across indications. ENBREL acts by binding tumor necrosis factor (TNF), one of the dominant inflammatory cytokines or regulatory proteins that play an important role in both normal immune function and the cascade of reactions that causes the inflammatory processes of rheumatoid arthritis. The binding of ENBREL to TNF renders the bound TNF biologically inactive, which can result in significant reduction in inflammatory activity.


'"/>

Contact: Jes Lauritzen
jes.lauritzen@ketchum.com
44-781-437-7386
Ketchum
22-Jun-2006


Page: 1 2 3 4 5

Related medicine news :

1. Rheumatoid arthritis and sex differences
2. Rheumatoid arthritis can be prevented if the timing is right
3. Rheumatoid arthritis drug linked to serious infections and cancers
4. Rheumatoid arthritis does not increase risk of hearing loss, Mayo Clinic study finds
5. Rheumatoid arthritis patients are more at risk of coronary artery disease
6. Using coxibs and NSAIDs to treat osteoarthritis
7. Experimental gene therapy abolishes arthritis pain and lessens joint damage
8. Counseling, coping skills could reduce arthritis disability
9. Green tea compound suppresses factors causing cartilage, bone destruction in arthritis
10. Green tea compound may be a therapy for people with rheumatoid arthritis
11. Costs of treating arthritis on the rise nationwide, study finds

Post Your Comments:
(Date:5/21/2013)... Dubuque, IA (PRWEB) May 21, 2013 Nearly ... took time out of an award trip in Los Cabos, ... Dia, a “day house” for the elderly. , The facility ... elderly residents of San Jose del Cabo, Mexico. , Platinum ... project began while reflecting on the company’s history. , “Platinum ...
(Date:5/21/2013)... Everspark Interactive, one of the city's leading ... over the past year – and announced another milestone ... marketing efforts for Kids II, a designer of innovative ... a local effort, specializing in search engine optimization (SEO) ... company's website. The company now offers a host of ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Workplace ... world’s leading work-life services provider, and Mayo Clinic ... wellness services. In an initiative set to launch ... Clinic’s coaching model into its existing suite of ... Clinic’s current commercial client base in addition to ...
(Date:5/21/2013)... AAG Health, the leading age management and hormone ... has acquired the OligoScan test made by leading European ... technology, the OligoScan device is capable of measuring in ... metals, 20 trace elements (minerals), and oxidative stress levels. ... as mercury, lead, aluminum, and arsenic, will make it ...
(Date:5/21/2013)... Thousands of Americans, many of them smokers or ... chronic obstructive pulmonary disease (COPD). Now a new ... antibiotic azithromycin may be able to cut down ... "Given that exacerbations of COPD can be ... Victoria Richards, assistant professor of medical science at ...
Breaking Medicine News(10 mins):Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3Health News:Everspark Named Interactive Marketing Company for Kids II 2Health News:Workplace Options and Mayo Clinic Announce Strategic Relationship 2Health News:Workplace Options and Mayo Clinic Announce Strategic Relationship 3Health News:AAG Health is the First Age Management Center in Florida to Offer the OligoScan 2Health News:AAG Health is the First Age Management Center in Florida to Offer the OligoScan 3Health News:Long-Term Use of Antibiotic May Help Those With COPD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 3
(Date:5/21/2013)... May 21, 2013  Lehigh Valley Health Network has ... devices, adding to its existing arsenal of five ... up residence within the network, LVHN is now deploying ... proactively combat superbugs and provide the best possible patient ... Ultraviolet Disinfector, TRU-D – the signature product of ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... , May 21, 2013  BioRestorative Therapies, Inc. ("BRT" ... company focused on developing stem cell based therapies for ... , its President and CEO, will be presenting ... conference will be held on Thursday, May 30, 2013 ... 42nd Street in New York City.  Mr. Weinreb,s presentation ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
Cached News: